Listed

Microbot Medical Inc.

MBOTNasdaqCIK 883975HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$241.0kRevenue, Q2 FY2026, three months to 2026-06-30$241.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001493152-26-037009.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 11, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$241.0kRevenue, Q2 FY2026, three months to 2026-06-30$241.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001493152-26-037009.Report this figureNo year-earlier figure to compare
  • Gross margin−266.8%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: −$643.0k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-11, accession 0001493152-26-037009.Revenue: $241.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001493152-26-037009.Report this figureNo year-earlier figure to compare
  • Operating margin−2567.6%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$6.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001493152-26-037009.Revenue: $241.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001493152-26-037009.Report this figureNo year-earlier figure to compare
  • Net margin−2334.9%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$5.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001493152-26-037009.Revenue: $241.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001493152-26-037009.Report this figureNo year-earlier figure to compare
  • Diluted EPS−$0.08Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001493152-26-037009.Report this figure+20.0% on a year earlier
  • Free cash flow−$5.1mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$5.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001493152-26-037009. Derived: 6-month figure less the 3-month figure.Capital expenditure: $142.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001493152-26-037009. Derived: 6-month figure less the 3-month figure.Report this figure−98.7% on a year earlier

Last eight quarters

Full statements
Revenue$241.0kGross margin −266.8%
Diluted EPS−$0.08, Q2 FY2026
Free cash flow−$5.1m, Q2 FY2026
Microbot Medical Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$knot reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)105Revenue, Q1 FY2026, three months to 2026-03-31$105.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001493152-26-022792.Report this figure241Revenue, Q2 FY2026, three months to 2026-06-30$241.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001493152-26-037009.Report this figure
Gross margin%not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)1.9%Gross margin, Q1 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $2.0k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-13, accession 0001493152-26-022792.Revenue: $105.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001493152-26-022792.Report this figure(266.8%)Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: −$643.0k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-11, accession 0001493152-26-037009.Revenue: $241.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001493152-26-037009.Report this figure
Operating margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)(4114.3%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$4.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001493152-26-022792.Revenue: $105.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001493152-26-022792.Report this figure(2567.6%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$6.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001493152-26-037009.Revenue: $241.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001493152-26-037009.Report this figure
Net margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)(3496.2%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$3.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001493152-26-037009.Revenue: $105.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001493152-26-022792.Report this figure(2334.9%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$5.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001493152-26-037009.Revenue: $241.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001493152-26-037009.Report this figure
Diluted EPS$ per share(0.20)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001493152-25-021929.Report this figurenot reported (Diluted EPS not reported)(0.08)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001493152-26-022792.Report this figure(0.10)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001493152-26-037009.Report this figure(0.07)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001493152-25-021929.Report this figurenot reported (Diluted EPS not reported)(0.05)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001493152-26-022792.Report this figure(0.08)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001493152-26-037009.Report this figure
Free cash flow$k(2,759)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$2.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001493152-25-021929. Derived: 9-month figure less the 6-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001493152-25-021929. Derived: 9-month figure less the 6-month figure.Report this figure(1,698)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$1.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001493152-26-012935. Derived: 12-month figure less the 9-month figure.Capital expenditure: $7.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-26, accession 0001493152-26-012935. Derived: 12-month figure less the 9-month figure.Report this figure(2,887)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$2.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001493152-26-022792.Capital expenditure: $13.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001493152-26-022792.Report this figure(2,582)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$2.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001493152-26-037009. Derived: 6-month figure less the 3-month figure.Capital expenditure: $9.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001493152-26-037009. Derived: 6-month figure less the 3-month figure.Report this figure(3,854)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$3.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001493152-25-021929. Derived: 9-month figure less the 6-month figure.Capital expenditure: $13.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001493152-25-021929. Derived: 9-month figure less the 6-month figure.Report this figure(3,783)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$3.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001493152-26-012935. Derived: 12-month figure less the 9-month figure.Capital expenditure: $25.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-26, accession 0001493152-26-012935. Derived: 12-month figure less the 9-month figure.Report this figure(5,161)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$5.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001493152-26-022792.Capital expenditure: $108.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001493152-26-022792.Report this figure(5,131)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$5.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001493152-26-037009. Derived: 6-month figure less the 3-month figure.Capital expenditure: $142.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001493152-26-037009. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Diluted EPS−$0.29, FY2025
Free cash flow−$13.1m, FY2025
Microbot Medical Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$mnot reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Gross margin%not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)
Operating margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Net margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Diluted EPS$ per share(1.59)Diluted EPS, FY2021, twelve months to 2021-12-31−$1.59 per share. XBRL concept us-gaap:EarningsPerShareBasicAndDiluted. 10-K filed 2022-03-31, accession 0001493152-22-008344.Report this figure(1.81)Diluted EPS, FY2022, twelve months to 2022-12-31−$1.81 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-27, accession 0001493152-24-011521.Report this figure(1.05)Diluted EPS, FY2023, twelve months to 2023-12-31−$1.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-25, accession 0001641172-25-000614.Report this figure(0.73)Diluted EPS, FY2024, twelve months to 2024-12-31−$0.73 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-26, accession 0001493152-26-012935.Report this figure(0.29)Diluted EPS, FY2025, twelve months to 2025-12-31−$0.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-26, accession 0001493152-26-012935.Report this figure
Free cash flow$m(9.4)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$9.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-03-31, accession 0001493152-23-010223.Capital expenditure: $69.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-03-31, accession 0001493152-23-010223.Report this figure(11.6)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$11.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-27, accession 0001493152-24-011521.Capital expenditure: $84.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-27, accession 0001493152-24-011521.Report this figure(8.6)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$8.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-25, accession 0001641172-25-000614.Capital expenditure: $33.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-25, accession 0001641172-25-000614.Report this figure(8.9)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$8.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001493152-26-012935.Capital expenditure: $25.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-26, accession 0001493152-26-012935.Report this figure(13.1)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$13.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001493152-26-012935.Capital expenditure: $60.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-26, accession 0001493152-26-012935.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Microbot Medical Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$5.7m2,906,810Reduced−2,715
Mitsubishi UFJ Asset Management Co., Ltd.2026-06-30$2.5m1,268,453New+1,268,453
BlackRock, Inc.2026-06-30$1.8m902,411Added+45,013
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$1.6m836,271Added+75,440
UBS Group AG2026-06-30$1.6m806,847Reduced−10,098
DNB Asset Management AS2026-06-30$1.3m677,498Unchanged
STIFEL FINANCIAL CORP2026-06-30$1.2m589,924Added+16,849
MARSHALL WACE, LLP2026-06-30$1.1m541,963Added+60,918
SUSQUEHANNA INTERNATIONAL GROUP, LLP2026-06-30$1.0m525,827Reduced−398,480
VANGUARD FIDUCIARY TRUST CO2026-06-30$840.5k431,033Added+30,808

Recent filings

All 1,139 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Microbot Medical Inc., recent filings
FiledFormWhat it isAccession number
2026-10-2308:30 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-26-048182
2026-10-2008:30 ET8-K5.08 Item not in the standard list; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-26-047702
2026-10-0608:30 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-26-045866
2026-09-2806:24 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-26-044429
2026-08-1110:28 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-26-037031
2026-08-1109:15 ET10-QQuarterly reportPeriod 2026-06-300001493152-26-037009
2026-08-0716:30 ET8-K1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001493152-26-036600
2026-07-2108:30 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-26-034014
2026-07-0708:30 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001493152-26-032260
2026-06-3008:30 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001493152-26-031205

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
883975
Tickers
MBOT
Exchange
Nasdaq
SIC code
3841 Surgical & Medical Instruments & Apparatus
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company
Former names
Microbot Medical Inc. (to 2026-10-23); STEMCELLS INC (to 2016-11-15); CYTOTHERAPEUTICS INC/DE (to 2000-05-15)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 08:31 ET. Listed shows no prices and gives no investment advice.